Trial Profile
Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary)
- Indications Cancer metastases; Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PROSPER
- 18 Sep 2023 Planned End Date changed from 30 Nov 2023 to 30 Nov 2025.
- 05 Sep 2023 Planned End Date changed from 31 Dec 2021 to 30 Nov 2023.
- 17 Nov 2020 Planned End Date changed from 30 Nov 2019 to 31 Dec 2021.